Sangamo Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.9079
- Today's High:
- $1.01
- Open Price:
- $0.9319
- 52W Low:
- $0.77
- 52W High:
- $5.8
- Prev. Close:
- $0.93
- Volume:
- 822853
Company Statistics
- Market Cap.:
- $164.73 million
- Book Value:
- 1.319
- Revenue TTM:
- $218.48 million
- Operating Margin TTM:
- -48.47%
- Gross Profit TTM:
- $-138599000
- Profit Margin:
- -90.86%
- Return on Assets TTM:
- -14.05%
- Return on Equity TTM:
- -71.93%
Company Profile
Sangamo Therapeutics Inc had its IPO on 2000-04-06 under the ticker symbol SGMO.
The company operates in the Healthcare sector and Biotechnology industry. Sangamo Therapeutics Inc has a staff strength of 478 employees.
Stock update
Shares of Sangamo Therapeutics Inc opened at $0.93 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.91 - $1.01, and closed at $0.99.
This is a +6.83% increase from the previous day's closing price.
A total volume of 822,853 shares were traded at the close of the day’s session.
In the last one week, shares of Sangamo Therapeutics Inc have increased by +1.38%.
Sangamo Therapeutics Inc's Key Ratios
Sangamo Therapeutics Inc has a market cap of $164.73 million, indicating a price to book ratio of 1.8288 and a price to sales ratio of 4.8262.
In the last 12-months Sangamo Therapeutics Inc’s revenue was $218.48 million with a gross profit of $-138599000 and an EBITDA of $-91769000. The EBITDA ratio measures Sangamo Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sangamo Therapeutics Inc’s operating margin was -48.47% while its return on assets stood at -14.05% with a return of equity of -71.93%.
In Q2, Sangamo Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 76.7%.
Sangamo Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.11 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sangamo Therapeutics Inc’s profitability.
Sangamo Therapeutics Inc stock is trading at a EV to sales ratio of 2.6016 and a EV to EBITDA ratio of -1.7582. Its price to sales ratio in the trailing 12-months stood at 4.8262.
Sangamo Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $325.07 million
- Total Liabilities
- $53.79 million
- Operating Cash Flow
- $42.47 million
- Capital Expenditure
- $5.54 million
- Dividend Payout Ratio
- 0%
Sangamo Therapeutics Inc ended 2024 with $325.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $325.07 million while shareholder equity stood at $233.64 million.
Sangamo Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $53.79 million in other current liabilities, 1771000.00 in common stock, $-1241918000.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $66.83 million and cash and short-term investments were $143.10 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Sangamo Therapeutics Inc’s total current assets stands at $159.61 million while long-term investments were $39.04 million and short-term investments were $76.27 million. Its net receivables were $3.94 million compared to accounts payable of $14.84 million and inventory worth $0.
In 2024, Sangamo Therapeutics Inc's operating cash flow was $42.47 million while its capital expenditure stood at $5.54 million.
Comparatively, Sangamo Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.99
- 52-Week High
- $5.8
- 52-Week Low
- $0.77
- Analyst Target Price
- $6.01
Sangamo Therapeutics Inc stock is currently trading at $0.99 per share. It touched a 52-week high of $5.8 and a 52-week low of $5.8. Analysts tracking the stock have a 12-month average target price of $6.01.
Its 50-day moving average was $1.14 and 200-day moving average was $2.03 The short ratio stood at 6.66 indicating a short percent outstanding of 0%.
Around 1442.7% of the company’s stock are held by insiders while 6568.9% are held by institutions.
Frequently Asked Questions About Sangamo Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.